The impact of circulating 25-hydroxyvitamin and oral cholecalciferol treatment on menstrual pain in dysmenorrheic patients

Basit Öğe Kaydı
dc.contributor.authorKucukceran, Hatice
dc.contributor.authorOzdemir, Ozhan
dc.contributor.authorKiral, Serkan
dc.contributor.authorBerker, Dilek Sensoz
dc.contributor.authorKahveci, Rabia
dc.contributor.authorOzkara, Adem
dc.contributor.authorAtalay, Cemal Resat
dc.date.accessioned2024-02-23T14:20:19Z
dc.date.available2024-02-23T14:20:19Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractThis study aims to determine Vitamin-D level in patients with primary dysmenorrhea and investigate the effect of Vitamin-D replacement on symptoms. About 100 patients in the 18-30 age group followed-up with primary dysmenorrhea diagnosis were included in this observational study. The pain severity was assessed using the visual analog scale (VAS). 25-hydroxy vitamin D(25(OH)D) levels of the patients were measured and the replacement therapy was applied according to measurement results. The patients were followed for three months in total. At the end of the three-month period, the 25(OH)D level was measured and the VAS score was assessed once more after the therapy. 25(OH)D level was insufficient in 23.0%, deficient in 45.0%, and severely deficient in 32.0% of the patients. It was found that the VAS score increased as the 25(OH)D level decreased (r = -0.320; p = .002). A significant reduction was observed in VAS scores after Vitamin-D treatment in all three groups; the amount of reduction in VAS score was determined to be higher in the patients with severely deficient levels of 25(OH)D, compared to the patients with deficient or insufficient levels (p < .001). A significant and negative correlation was found between Vitamin-D and symptoms associated with dysmenorrhea in our study. The Vitamin-D replacement therapy led to a significant decrease in symptoms.en_US
dc.identifier.doi10.1080/09513590.2018.1490407
dc.identifier.endpage57en_US
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issue1en_US
dc.identifier.pmid30044160en_US
dc.identifier.scopus2-s2.0-85050682724en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage53en_US
dc.identifier.urihttps://doi.org/10.1080/09513590.2018.1490407
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13115
dc.identifier.volume35en_US
dc.identifier.wosWOS:000459591100012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofGynecological Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPrimary Dysmenorrheaen_US
dc.subjectPthen_US
dc.subjectVas Scoreen_US
dc.subjectVitamin-Den_US
dc.titleThe impact of circulating 25-hydroxyvitamin and oral cholecalciferol treatment on menstrual pain in dysmenorrheic patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu